TY - JOUR
T1 - Docetaxel for malignant mesothelioma
T2 - Phase II study of the Eastern Cooperative Oncology Group
AU - Belani, Chandra P.
AU - Adak, Sudeshna
AU - Aisner, Seena
AU - Stella, Philip J.
AU - Levitan, Nathan
AU - Johnson, David H.
PY - 2004/7
Y1 - 2004/7
N2 - This Eastern Cooperative Oncology Group phase II trial was conducted to study the effectiveness of docetaxel in patients with malignant mesothelioma. Patients were treated with docetaxel 100 mg/m2 intravenously administered as a 1-hour infusion repeated every 3 weeks. The study accrued a total of 20 patients, 1 of whom was considered ineligible. Of the 19 eligible patients, 1 patient (5%) achieved a partial response, 3 patients (16%) had stable disease, 11 patients (58%) had progressive disease, and 4 patients (21%) were unevaluable. The study was terminated after the first accrual stage because of an insufficient number of complete or partial responses. To date, only 1 patient (with stable disease) has not relapsed. The estimated median survival time is 4 months and the estimated median time to treatment failure is 2.2 months. There were 3 early deaths associated with the treatment regimen: severe gastrointestinal toxicity, hemorrhage, and an acute pulmonary event. Docetaxel as a single agent does not demonstrate evidence of activity in malignant mesothelioma.
AB - This Eastern Cooperative Oncology Group phase II trial was conducted to study the effectiveness of docetaxel in patients with malignant mesothelioma. Patients were treated with docetaxel 100 mg/m2 intravenously administered as a 1-hour infusion repeated every 3 weeks. The study accrued a total of 20 patients, 1 of whom was considered ineligible. Of the 19 eligible patients, 1 patient (5%) achieved a partial response, 3 patients (16%) had stable disease, 11 patients (58%) had progressive disease, and 4 patients (21%) were unevaluable. The study was terminated after the first accrual stage because of an insufficient number of complete or partial responses. To date, only 1 patient (with stable disease) has not relapsed. The estimated median survival time is 4 months and the estimated median time to treatment failure is 2.2 months. There were 3 early deaths associated with the treatment regimen: severe gastrointestinal toxicity, hemorrhage, and an acute pulmonary event. Docetaxel as a single agent does not demonstrate evidence of activity in malignant mesothelioma.
UR - http://www.scopus.com/inward/record.url?scp=4444330118&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4444330118&partnerID=8YFLogxK
U2 - 10.3816/CLC.2004.n.020
DO - 10.3816/CLC.2004.n.020
M3 - Article
C2 - 15310416
AN - SCOPUS:4444330118
SN - 1525-7304
VL - 6
SP - 43
EP - 47
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 1
ER -